Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid

This study confirmed that the Mycobacterium tuberculosis complex lineage 1, responsible for 28% of global tuberculosis cases, is less susceptible to pretomanid (Pa). It also refined the understanding of the intrinsic susceptibilities of lineages 5 and 6, most frequent in West Africa, and lineages 8...

Full description

Saved in:
Bibliographic Details
Published in:Microbiology spectrum Vol. 12; no. 3; p. e0007024
Main Authors: Rupasinghe, Praharshinie, Reenaers, Rabab, Vereecken, Jens, Mulders, Wim, Cogneau, Sari, Merker, Matthias, Niemann, Stefan, Vally Omar, Shaheed, Rigouts, Leen, Köser, Claudio U., Decroo, Tom, de Jong, Bouke C.
Format: Journal Article
Language:English
Published: United States American Society for Microbiology 05.03.2024
Subjects:
Antimicrobial Chemotherapy
MTBC lineages
Mycobacterium tuberculosis
pretomanid
Research Article
Mycobacterium tuberculosis
pretomanid
MTBC lineages
ISSN:2165-0497, 2165-0497
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study confirmed that the Mycobacterium tuberculosis complex lineage 1, responsible for 28% of global tuberculosis cases, is less susceptible to pretomanid (Pa). It also refined the understanding of the intrinsic susceptibilities of lineages 5 and 6, most frequent in West Africa, and lineages 8 and 9. Regulators must review whether these in vitro differences affect the clinical efficacy of the WHO-recommended BPaL(M) regimen and set breakpoints for antimicrobial susceptibility testing accordingly. Notably, regulators should provide detailed justifications for their decisions to facilitate public scrutiny.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
C.U.K. is a consultant for Becton Dickinson, the Foundation for Innovative New Diagnostics, the TB Alliance, and the WHO Global TB Programme. C.U.K.'s consulting for Becton Dickinson involves collaboration with Janssen and Thermo Fisher Scientific. C.U.K. is collaborating with PZA Innovation and is an unpaid advisor to Cepheid and GenoScreen (GenoScreen covered related travel and accommodation expenses only). C.U.K. worked as a consultant for the Stop TB Partnership and the WHO Regional Office for Europe. C.U.K. gave a paid educational talk for Oxford Immunotec. C.U.K. was an unpaid advisor to BioVersys.
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.00070-24